4.7 Article

Viral protein engagement of GBF1 induces host cell vulnerability through synthetic lethality

Journal

JOURNAL OF CELL BIOLOGY
Volume 221, Issue 11, Pages -

Publisher

ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.202011050

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01 GM112108, P41 GM109824, R21 AI151344]
  2. Canadian Institutes of Health Research [FDN-167277]

Ask authors/readers for more resources

Using a viral-induced hypomorph of GBF1, this study demonstrates that the principle of synthetic lethality can selectively kill virus-infected cells. Viral protein interactions can induce hypomorphs in host cells, making them selectively vulnerable to perturbations.
Using a viral-induced hypomorph of GBF1, Navare et al. demonstrate that the principle of synthetic lethality is a mechanism to selectively kill virus-infected cells. Viruses co-opt host proteins to carry out their lifecycle. Repurposed host proteins may thus become functionally compromised; a situation analogous to a loss-of-function mutation. We term such host proteins as viral-induced hypomorphs. Cells bearing cancer driver loss-of-function mutations have successfully been targeted with drugs perturbing proteins encoded by the synthetic lethal (SL) partners of cancer-specific mutations. Similarly, SL interactions of viral-induced hypomorphs can potentially be targeted as host-based antiviral therapeutics. Here, we use GBF1, which supports the infection of many RNA viruses, as a proof-of-concept. GBF1 becomes a hypomorph upon interaction with the poliovirus protein 3A. Screening for SL partners of GBF1 revealed ARF1 as the top hit, disruption of which selectively killed cells that synthesize 3A alone or in the context of a poliovirus replicon. Thus, viral protein interactions can induce hypomorphs that render host cells selectively vulnerable to perturbations that leave uninfected cells otherwise unscathed. Exploiting viral-induced vulnerabilities could lead to broad-spectrum antivirals for many viruses, including SARS-CoV-2.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available